Elicio Therapeutics, Inc.

ELTX Healthcare Biotechnology

EPS
+34.9%
Free cash flow
+8.77%
Total debt
+2.12%

Quarter to June 2026, against a year earlier

1.52 0.12 +8.57%
Market cap
$37.9M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
6/9
Altman Z
0.10
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.77 2.24 2.38 3.29
Net Debt/EBITDA
1.38 0.53 1.09 1.40
Debt/Equity
1.20 (6.59) 5.75 2.55
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.42) (0.64) (0.44) (0.66)
Book value per Share
0.41 (0.08) 0.11 0.23
Free Cash Flow
(8.16) (11.64) (6.81) (11.09)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026